Salute e Benessere
Scleroderma Market to Reach US$ 4,103.07 Million by 2033 as Biologics, Targeted Therapies, and Early Diagnosis Transform Patient Outcomes | Report by DataM Intelligence
The rising prevalence of autoimmune disorders, coupled with improved disease awareness and supportive regulatory frameworks, positions the scleroderma market for sustained growth in the next decade.
Its severe complications involving the lungs, kidneys, and cardiovascular system make it the focal point of research investments. Pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD) remain critical therapeutic targets.
accounted for 35% of market revenues in 2024. Though less life-threatening, localized variants significantly affect patient quality of life and are driving demand for topical and biologic therapies.
with immunosuppressants, corticosteroids, and antifibrotic drugs leading prescriptions. Biologics and targeted therapies under development are expected to expand this segment significantly by 2030.
remain necessary for severe systemic cases involving organ damage and vascular complications. Advances in reconstructive surgery and vascular bypass techniques are improving survival rates.
reflecting their central role in systemic scleroderma management and advanced surgical interventions.
as patients transition to outpatient and long-term biologic therapies.
The U.S., valued at leads the global market. Growth is driven by:
Japan's market, valued at is expanding due to:
Roche leads the systemic scleroderma ILD treatment space with . In 2024, Roche generated and continues investing in biomarker-driven trials.
Boehringer's remains a cornerstone therapy for systemic sclerosis-ILD. With 2025 clinical data supporting long-term lung function preservation, the company is expanding its market reach.
GSK is advancing biologics targeting . Its ongoing collaborations with academic institutions in the U.S. highlight a strong innovation strategy.
Both companies maintain strong autoimmune portfolios. Novartis is advancing next-gen ILD biologics in Japan , while Pfizer is investing in to improve treatment adherence.
is advancing fibrosis-modulating drugs. are exploring adjunctive bioresorbable solutions for reconstructive surgery in scleroderma patients.
The is at a critical inflection point. Four trends will shape its trajectory:
The reflects a rare disease segment undergoing profound transformation. With the U.S. leading systemic therapy adoption and Japan pioneering precision medicine, the market offers
DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specializes in strategic reports that guide businesses in high-growth sectors such as nutraceuticals and AI-driven health innovations.
To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter , LinkedIn and Facebook .
Sai Kiran
DataM Intelligence 4market Research LLP
Ground floor, DSL Abacus IT Park, Industrial Development Area
Uppal, Hyderabad , Telangana 500039
+1 877-441-4866
Sai.k@datamintelligence.com https://www.datamintelligence.com/
Logo: https://mma.prnewswire.com/media/1858619/3573087/DataM_Intelligence_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/scleroderma-market-to-reach-us-4-103-07-million-by-2033-as-biologics-targeted-therapies-and-early-diagnosis-transform-patient-outcomes--report-by-datam-intelligence-302572304.html